Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:10 2024-05-10 am EDT			5-day change	1st Jan Change
225.1 ^CHF	+1.26%		+3.59%	-7.93%

May. 10	Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar	MT
May. 07	Enable Injections, Inc. Announces Collaboration with Roche to Develop and Commercialize Combination of the enFuse Technology with Specific Roche Development Programs	CI

ROCHE HOLDINGS AG : UBS reiterates its Buy rating

September 30, 2020 at 08:04 am EDT

In a research note published by Michael Leuchten, UBS advises its customers to buy the stock. The target price continues to be set at CHF 390.

Latest news about Roche Holding AG

Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar	May. 10	MT
Enable Injections, Inc. Announces Collaboration with Roche to Develop and Commercialize Combination of the enFuse Technology with Specific Roche Development Programs	May. 07	CI
ROCHE HOLDINGS AG : UBS reiterates its Neutral rating	May. 06	ZD
Swiss Equities Close in Red Amid Inflation Spotlight	Apr. 29	MT
Roche Holding AG: slimming down	Apr. 29
Roche: positive opinion from CHMP for subcutaneous Ocrevus	Apr. 29	CF
European Medicines Agency Committee Backs Roche's Subcutaneous Injection for Multiple Sclerosis	Apr. 29	MT
Roche: positive CHMP opinion for Alecensa	Apr. 26	CF
Roche’s Lung Cancer Drug Alecensa Backed for Approval in EU	Apr. 26	MT
The specter of stagflation rears its ugly head again	Apr. 25
ROCHE : Barclays lowers target price	Apr. 25	CF
Scholz pledges further support for the pharmaceutical industry	Apr. 25	DP
ROCHE HOLDINGS AG : UBS remains Neutral	Apr. 25	ZD
ROCHE HOLDINGS AG : Barclays sticks Neutral	Apr. 25	ZD
Scholz promises support for pharma sector in Germany as Merck invests	Apr. 25	RE
Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5%	Apr. 25	MT
ROCHE HOLDINGS AG : DZ Bank reiterates its Buy rating	Apr. 24	ZD
Roche’s Downbeat Q1 Sales Drag Swiss Market Index to Red	Apr. 24	MT
ROCHE HOLDING : In line quarterly results won’t cut it for Roche	Apr. 24
Global markets live: Heineken, AT&T Hasbro, Visa, Boeing...	Apr. 24
Transcript : Roche Holding AG, Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024	Apr. 24
ROCHE HOLDINGS AG : Barclays remains Neutral	Apr. 24	ZD
ROCHE HOLDINGS AG : UBS reaffirms its Neutral rating	Apr. 24	ZD
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	Apr. 24	RE
Roche Eyes Potential M&A Deals Amid Pipeline Restructure	Apr. 24	MT

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

2024-05-14 - BofA Securities Health Care Conference

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 11:50 am EDT

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am EST

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

225.1 CHF

Average target price

279.4 CHF

Spread / Average Target

+24.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	-7.93%	200B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
AMGEN INC.	+7.68%	166B
PFIZER, INC.	-2.71%	159B

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

ROCHE HOLDINGS AG : UBS reiterates its Buy rating

Latest news about Roche Holding AG

Chart Roche Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Roche Holding AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals